Robustness of solvent/detergent treatment of plasma derivatives: A data collection from Plasma Protein Therapeutics Association member companies

Transfusion

Volumn 49, Issue 9, 2009, Pages 1931-1943

  Dichtelmüller, Herbert O ^{a,b,c,d,e,f,g}   Biesert, Lothar ^{a,b,c,d,e,f,g}   Fabbrizzi, Fabrizio ^{a,b,c,d,e,f,g}   Gajardo, Rodrigo ^{a,b,c,d,e,f,g}   Gröner, Albrecht ^{a,b,c,d,e,f,g}   Von Hoegen, Ilka ^{a,b,c,d,e,f,g,h}   Jorquera, Juan I ^{a,b,c,d,e,f,g}   Kempf, Christoph ^{a,b,c,d,e,f,g}   Kreil, Thomas R ^{a,b,c,d,e,f,g}   Pifat, Dominique ^{a,b,c,d,e,f,g}   Osheroff, Wendy ^{a,b,c,d,e,f,g}   Poelsler, Gerhard ^{a,b,c,d,e,f,g}  

^a BIOTEST AG   (Germany)

^b Octapharma   (Germany)

^c Kedrion ^*  (Spain)

^d CSL BEHRING GMBH   (Germany)

^e CSL Behring AG   (Switzerland)

^f BAXTER BIOSCIENCE   (Austria)

^g Talecris   (United States)

^h PPTA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHOLIC ACID; DETERGENT; IMMUNOGLOBULIN; PLASMA PROTEIN; POLYSORBATE 80; SOLVENT; TRIBUTYL PHOSPHATE; TRITON X 100;

ARTICLE; DRUG MANUFACTURE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PLASMA; RELIABILITY; ROBUSTNESS; SOLVENT DETERGENT TREATMENT; VIRUS ENVELOPE; VIRUS INACTIVATION;

BLOOD PROTEINS; CELL LINE; DETERGENTS; FACTOR IX; FACTOR VIII; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA; SOLVENTS; VIRUS INACTIVATION;

EID: 69249170993     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02222.x     Document Type: Article

References (19)

1. Prince AM, Horowitz B, Horowitz MS, Zang E. The development of virus-free labile blood derivatives - a review. Eur J Epidemiol 1987 3 : 103 18.
2. Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende M. Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang 1984 46 : 36 43.
3. Prince AM, Horowitz B, Brotman B. Sterilization of hepatitis and HTLV III viruses by exposure to tri-(n-butyl) phosphate and sodium cholate. Lancet 1986 i : 706 10.
4. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood products I. Disruption of lipid enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion 1985 25 : 516 22.
5. Alonso WR, Trukawinski S, Savage M, Tenold RA, Hammond DJ. Viral inactivation of intramuscular immune serum globulins. Biologicals 2000 28 : 5 15.
6. Horowitz B, Prince AM, Horowitz MS, Watklevicz C. Virus safety of solvent-detergent treated blood products. In : Brown F, editor. Virological safety aspects of plasma derivatives. Dev Biol Stand 1993 81 : 147 61. Basel : Karger.
7. Griffith M. Ultrapure plasma factor VIII produced by anti F VIIIc immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human). Ann Hematol 1991 63 : 131 7.
8. Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996 14 Suppl 15 : S47 S52.
9. Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95 rev).
10. Committee for Proprietary Medicinal Products. Note for guidance on plasma-derived medicinal products (CPMP/BWP/269/95, rev. 3).
11. ICH harmonised tripartite guideline: virus safety of biotechnology products derived from cell lines of human or animal origin Q5A. Geneve : ICH Steering Committee 1997.
12. Horowitz B, Minor P, Morgenthaler JJ, Burnouf T, McIntosh R, Padilla A, Thorpe R, van Aken WG WHO Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 2004 924 : 1 232.
13. Dichtelmüller H, Germer M, Rudnick D. A general approach to robustness studies. BioProcess Int 2005 Suppl : 35 8.
14. Kaerber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 1931 162 : 480.
15. Seitz H, Blümel J, Willkommen H, Löwer J. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment. Biologicals 2002 30 : 197 205.
16. Roberts P. Resistance of Vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals 2000 28 : 29 32.
17. Rabenau HF, Biesert L, Schmidt T, Bauer G, Cinatl J, Doerr HW. SARS-corona virus (SARS-CoV) and the safety of a solvent/detergent treated immunoglobulin preparation. Biologicals 2005 33 : 95 9.
18. Dichtelmüller H, Rudnick D, Breuer B, Kotitschke R, Kloft M, Darling A, Watson E, Flehmig B, Lawson S, Frösner G. Improvement of virus safety of a S/D treated Factor VIII concentrate by additional dry heat treatment at 100°C. Biologicals 1996 24 : 125 30.
19. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994 67 : 132 8.